LAUSR

Ventilator-associated pneumonia (VAP) has been claiming many lives in the ICU during COVID-19. Oral biofilm and bacterial contamination that can be passed on from the oral cavity to the lungs during endotracheal intubation has been found to be the main culprit. Bioluminescence-based assays are emerging as potential clinical diagnostics methods. Hence, we hypothesize that the bioluminescent imaging technique can be used in the ICU to determine the load of biofilm-associated with patients undergoing endotracheal intubation. Early detection of such infections and their management can effectively bring down mortality and influence the death rate in ICU caused due to VAP. Government agencies and policymakers should be made to take this issue of deaths in the ICU due to VAP more seriously and act judiciously to methods such as bioluminescence based on sound scientific evidence.